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Gynecologic surgeryAbstract Menorrhagia remains a significant health issue for women worldwide.
Traditionally hysterectomy has been the treatment of choice when excessive
menstrual bleeding remains unresolved by hormonal manipulation. In an attempt
to provide a less invasive alternative to hysterectomy, traditional techniques such as
rollerball endometrial ablation were developed 20 years ago. Although extremely
effective, they possessed the potential of significant intra-operative risks and their
success depended on high technical proficiency of the surgeon. As surgery and
technology evolved, second generation endometrial ablation devices were devel-
oped which demonstrated improved safety and efficacy rates that paralleled
traditional treatments. Since 1997, the Food and Drug Administration (FDA) has
approved five such devices for use in the United States. Each possesses a unique
technology profile with supporting level I evidence that allows for the treatment of a
wide variety of uterine anatomy.
D 2006 International Federation of Gynecology and Obstetrics. Published by Elsevier
Ireland Ltd.1. Introduction
Approximately 20—25% of healthy premenopasual
women have abnormal uterine bleeding. The
prevalence of abnormal uterine bleeding increases
with age, peaking at about the fifth decade of
life. Approximately 600,000 hysterectomies are6 International Federation of G
nvasive Surgery Program
tetrics and Gynecology,
L 4000 Women’s Hospital,
Arbor, MI 48109, United
734 647 9727.
du (A.P. Advincula).performed annually each year in the United States
and it is estimated that 20% to 25% of these are to
relieve excessive menstrual bleeding unresolved
by medical management [1]. Data from 1988—
1993 indicate that more than one quarter of
women will have a hysterectomy by the age of
60. The highest hysterectomy rates are for women
ages 40—44 [2].
Alternative methods to hysterectomy have been
explored for many years. Endometrial ablation,
defined as the elimination of the endometrium by
thermal energy or resection, was introduced in the
1980’s as an alternative for patients with abnormal
uterine bleeding. DeChernery and Polan describedInternational Journal of Gynecology and Obstetrics (2006) 94, 156—166ynecology and Obstetrics. Published by Elsevier Ireland Ltd.
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with menometrorrhagia [3]. Soon thereafter, roll-
erball ablation was introduced in Japan in 1988 and
in the United States in 1989 [4,5]. Rollerball
ablation soon evolved into the most widely used
hysteroscopic ablation technique because of its
ease of use, and decreased risks of complications.
In 1990, a modification using a continuous-flow
resectoscope and low-viscosity distention fluid to
perform transcervical resection of the endometri-
um was described [6]. These techniques became
known as first generation endometrial ablations. A
Cochrane database analysis of first generation
endometrial ablations versus hysterectomy showed
that they were a reasonable alternative to hyster-
ectomy with high efficacy and satisfaction rates
[7]. However, these first generation systems were
highly operator skill dependent, with operative
risks of uterine perforation, cervical laceration
and intra-operative fluid overload that resulted in
electrolyte abnormalities.
The second generation endometrial ablation
devices were introduced in the early 1990’s as
alternatives to the first generation devices. They
were developed in an effort to simplify the ablative
procedure but provide efficacy that parallels
traditional hysteroscopic modalities. The second
generation devices were intended to involve less
skill and training, and ideally be able to be
performed under local anesthesia. There have been
5 second generation devices that have been
approved by the Food and Drug Administration
(FDA) for use in the United States. The initial data
on these five devices were reported as case series
and observational studies (level III evidence). In
order to gain FDA approval, these second genera-
tion devices were put through randomized con-
trolled trials that compared them with traditional
hysteroscopic rollerball (RB) ablation. This paper
will review the current level I evidence obtained
from randomized controlled trials that support the
safety and efficacy of these second generation
ablative devices.
In order to better interpret the following review
of second generation global endometrial ablation
devices, it is important to define menorrhagia. It is
often defined as menstrual bleeding in the ovula-
tory woman that lasts longer than 7 days, or
menstrual blood loss exceeding 80 ml. Many of
the following studies in turn utilize a validated
diary system known as a pictorial bleeding assess-
ment chart (PBAC) to help define menorrhagia. It
is a scoring system in which a score of 100
correlates with menstrual flow of approximately
80 ml [8]. Patients enrolled in studies are typically
defined as having menorrhagia with scores greaterthan 150 and success rates are often defined as a
score less than 75. Success rates as they relate to
changes in bleeding patterns will be discussed in
the cited studies supporting these various ablation
devices in addition to satisfaction rates and
complications. An overview of the technological
aspects of each device will precede a review of the
level I literature.
Candidates for any global endometrial ablation
are women with abnormal uterine bleeding refrac-
tory to medical therapies and who have endome-
trial biopsy proven absence of an endometrial
neoplasm. Typically, it is also required that the
uterine cavity be free of any endometrial polyps or
leiomyomata and that it be less than 10—12 cm in
length, although for many of the second generation
devices, these are not necessarily exclusionary. A
diagnostic hysteroscopy or saline infusion sonogra-
phy is usually performed prior to an ablative
procedure in order to confirm an appropriate
endometrial cavity.2. ThermaChoice Uterine Balloon
Therapy (UBT) system
2.1. Device
The concept of a thermal balloon ablation system
was first described in 1994 [9]. Several years later
in 1997, the Gynecare ThermaChoice Uterine
Balloon Therapy System became the first global
endometrial ablation device approved by the FDA.
Since its inception, not only has the UBT system
shown continued device improvements, but its
safety and efficacy has been demonstrated with
both short and long term results.
This method of global endometrial ablation
relies on a balloon that is filled with fluid (5%
dextrose and water) which in turn combines heat
and pressure within the uterine cavity to achieve
an effect. The balloon is designed to be able to
take up the shape of the endometrial cavity for
better coverage. The ThermaChoice I system
(Gynecare, Division of Ethicon, Somerville, NJ) is
the introductory model, and consist of a controller,
and a disposable 16 cm long, 4.5 mm diameter
catheter with a latex balloon attached to its distal
end. Minimal cervical dilation is required. The
balloon is tested for leaks, and then primed by
inflating it with several milliliters of 5% dextrose
and water. The balloon is then deflated to a
pressure of approximately negative 180 mm of
Hg. The catheter is then inserted into the uterine
cavity and inflated to approximately 180 mm of Hg,
H. Morgan, A.P. Advincula158at which point the fluid is heated to 87 8C for a
total treatment time of 8 min.
The ThermaChoice II system, introduced in 1998,
improved upon the first generation device by
providing a small impeller inside the balloon to
circulate fluid during the procedure. In addition,
the balloon material was changed to silicone from
latex. The ThermaChoice III system, introduced in
2004, had an additional modification to the silicone
balloon for better coverage and expansion within
the uterine cavity.
2.2. Literature
Of all the second generation endometrial ablation
devices, there has been the most experience with
the ThermaChoice system in the United States. All
of the randomized controlled trials for this method
of ablation to date have been performed with the
ThermaChoice I system.
A large multi-center randomized controlled trial
of ThermaChoice I (UBT) versus rollerball (RB)
ablation was performed in 1996, with results
reported at the 1, 2, 3 and 5 year follow up
intervals. Meyer et al. first reported the 1 year
results [10]. 255 women with a PBAC score greater
than 150 were randomized at a 1:1 ratio to UBT
versus RB ablation with 239 available for evalua-
tion at year’s end. There was no medicinal
pretreatment regimen administered however a 3
min curettage using a 5 mm suction curette was
completed before ablation by either technique.
80.2% of the UBT patients and 84.3% of the RB
patients reported a return to normal bleeding or
less (PBAC score of less than 100). On the other
hand, a greater percentage of women in the RBTable 1 ThermaChoice Uterine Balloon Therapy (UBT) sys
Author, patients Efficacy findings
Meyer et al. (1 year data)
Grainger et al. (2 year data)
Loffer FD (3 year data)
UBT:
1 year: 80.2% reported normal
bleeding or less, 15.2% amenorr
Loffer et al. (5 year data)
ThermaChoice I (UBT)
2 year: 89.1% reported amenorr
or eumenorrhea
versus rollerball (RB)
ablation
3 year: 93% reported amenorrhe
or eumenorrhea
N =255 (study inception)
UBT=131
RB=124
5 year: 95% reported amenorrhe
or eumenorrhea
RB:
Follow up: 1, 2, 3, and 5 years 1 year: 84.3% reported normal
bleeding or less, 27.2% amenorr
2 year: 90.4% reported amenorr
or eumenorrhea.
3 year: 93.9% reported amenorr
or eumenorrhea.
5 year: 97% reported amenorrhe
or eumenorrhea.group (27.2%) compared with the UBT group
(15.2%) were amenorrheic at 1 year. Despite these
findings, 85.6% of the UBT patients and 86.7% of
the RB patients were highly satisfied with their
results. Only 5 hysterectomies were performed
after treatment prior to 1 year follow up (2 UBT, 3
RB). There were four intra-operative complica-
tions in the RB arm and none in the UBT arm
(Table 1).
Grainger et al. reported a 2 year follow up data
on 227 evaluable patients [11]. 89.1% of the UBT
patients and 90.4% of the RB patients reported
amenorrhea or eumenorrhea. 11 (8.9%) hysterec-
tomies were performed in the RB arm, and 4
(3.0%) in the UBT arm. Satisfaction rates of 86.1%
and 86.7% were seen in the UBT and RB arms,
respectively. Loffer reported 3 year follow up data
on 214 evaluable patients [12]. 93.0% of the UBT
and 93.9% of the RB patients reported amenorrhea
or eumenorrhea. 8 (6.5%) of the UBT patients and
14 (14%) of the RB patients had hysterectomies
performed at 3 years. Satisfaction rates remained
high at 95.6% and 94% for the UBT and RB patients,
respectively. Loffer and Granger reported 5 year
follow up data [13]. 147 patients were available
for follow up of which 25 had undergone a
hysterectomy, repeat endometrial ablation or
dilation and curettage between years three and
five. Of those 122 left for analysis, 95% of the UBT
patients and 97% of the RB patients reported
amenorrhea or eumenorrhea. 93% of the UBT
patients and 100% of the RB patients were
satisfied with their procedure. Among the total
population of 255 patients originally enrolled in
the trial, 42 hysterectomies (21 UBT, 21 RB), 5
repeat endometrial ablations (3 UBT, 2 RB), andtem
Complications Reliability and validity issues
hea
4 intra-operative
complications with
RB ablation:
Study was not blinded
88% available for 2 year
follow up data
hea 1 cervical laceration
1 uterine perforation
83% available for 3 year
follow up data
a 2 fluid overload
UBT (none)
57% available for 5 year
follow up data
a
hea.
hea
hea
a
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(Table 1).
van Zon-Rabelink et al. performed a random-
ized controlled trial comparing UBT to RB ablation
[14]. 137 patients were randomized at a 1:1 ratio
to UBT versus RB ablation. Patients had menor-
rhagia based on a PBAC score of greater than 185.
All patients were treated with goserelin acetate 6
and 2 weeks preoperatively. The primary endpoint
was a reduction in PBAC score with the definition
of a study success being a PBAC score of less than
185 and a failure defined as continued menorrha-
gia with a PBAC score of greater than 185. This
differed from many other studies cited in this
review which define success as a PBAC score of
less than 75 (a marked reduction in bleeding).
Success rates were not statistically significant at
12 or 24 months postoperatively, and patient
satisfaction rates were also non-significant. They
found a higher risk for intra-operative complica-
tions with the 60 RB patients (3 uterine perfo-
rations and 3 cervix lacerations) that was
statistically significant. Both the UBT and RB arms
had intra-operative technical complications. Five
of the 77 UBT procedures were complicated by
control device error and four procedures were not
able to attain sufficient intrauterine pressure. Six
of the 60 RB procedures were complicated by a
nonfunctioning rollerball or fracture of the roller-
ball tip (Table 2) [15].
Advantages of the ThermaChoice Uterine Balloon
Therapy System are its ease of use, need for
minimal cervical dilation, and applicability to the
office setting. Pretreatment of the endometrium is
also optional. This system has also been used the
most extensively in the United States with long
term data confirming its safety and efficacy.
Additionally, this method of global endometrial
ablation is the only product that is FDA approved
for use with the EssureR system for permanent
contraception. The disadvantages are the blind
nature of the procedure without any hysteroscopic
visualization and the requirement of an anatomi-
cally normal cavity. In addition, the balloon mayTable 2 ThermaChoice Uterine Balloon Therapy (UBT) sys
Author, patients Efficacy findings Complicatio
van Zon-Rabelink et al.
ThermaChoice I (UBT)
versus rollerball
(RB) ablation
UBT:
Success: 78%
Patient satisfaction: 80%
RB:
Higher risk
complicatio
3 uterine p
3 cervix lac
N =137 Success: 76% 1 electrolyt
UBT=77 Patient satisfaction: 75% 1 suspicion
RB=60
Follow up=2 years
UBT (none)
Technical c
Technical cnot be able to fully ablate the residual endome-
trial tissue in the cornual regions of the uterus.
Finally, the study by van Zon-Rabelink et al. also
demonstrated that technical failure of either the
controller or the disposable balloon catheter can
compromise or sabotage the entire procedure.3. Hydro ThermAblator (HTA) system
3.1. Device
The Hydro ThermAblator System (Boston Scientific,
Natick, MA) is a global endometrial ablation device
developed in 1997, and approved by the FDA in
April 2001. This system delivers heated USP 0.9%
saline in a closed-loop system to the uterine cavity
under direct hysteroscopic guidance. Preliminary
studies on hysterectomy specimens demonstrate
that a 10 min circulation time at 90 8C achieves a
depth of necrosis from 3 to 4 mm throughout the
endometrial cavity in a uniform distribution [16].
Endometrial pretreatment is considered essential
since there is no endometrial compressive effect
during the treatment.
For this procedure, the cervix is dilated to 8 mm
to accept a 7.8 mm insulating sheath. This houses a
3 mm hysteroscope with inflow and outflow chan-
nels which are connected to a microprocessor-
based control system that contains a heating
element. The uterine cavity is distended with room
temperature normal saline. A tenaculum on the
cervix can assist with creating a leak-proof seal
around the instrument sheath. A 3 l saline bag is
elevated to 115 cm above the uterus which creates
a net intrauterine pressure of approximately 50 to
55 mm Hg. This hydrostatic pressure is well below
the threshold for opening the fallopian tubes. A
diagnostic hysteroscopy can be performed at this
time. The saline is then heated to 90 8C for the
actual treatment. This fluid is infused and returned
to the controller via a peristaltic pump in a closed-
loop system. The average treatment time is 10 min.tem
ns Reliability and validity issues
of intra-operative
ns with RB ablation:
erforations
erations
Study was not blinded
Definition of study success
e imbalance
of perforation
omplications with RB=10/62
omplications with UBT=13/77
H. Morgan, A.P. Advincula160There is an automatic shutdown if there is a loss of
10 ml or an increase of 20 ml of fluid.
3.2. Literature
Corson performed a multi-center prospective
randomized controlled trial which compared en-
dometrial ablation using the Hydro ThermAblator
(HTA) to rollerball (RB) ablation [17]. 276 patients
with PBAC’s greater than 150 for 3 months, with
no month having a score below 100 were enrolled
in the study. 187 were randomized to the HTA
arm, and 89 were randomized to the RB arm. All
patients received one pre-treatment dose of
depot leuprolide acetate 7.5 mg. Success was
defined as a PBAC score of less than 75 at 12
months. This was 77% in the HTA group and 82% in
the RB group, with no statistical significance
between the two groups. Amenorrhea rates at 1
year were 40% for the HTA group, and 51% for the
RB group, again with no statistical significance
between the two groups. Two the HTA partici-
pants had hysterectomies during the 12 month
follow up. One was for increasing symptoms from
an enlarging fibroid, and another was for unclear
reasons. There were two cervical lacerations in
the RB group, one of whom required hospitaliza-
tion for fever, nausea, vomiting and diarrhea that
was attributed to gram-negative septicemia.
There were none in the HTA group. Two patients
in the HTA group sustained first-degree burns, one
on the upper thigh and the other on the buttocks
from prolonged contact with the tubing that
carries heated saline from the control unit to
the hysteroscopic sheath. There were five cases
of hematometra in the RB group and only two in
the HTA group (Table 3).Table 3 Hydro ThermAblator (HTA) system
Author, patients Efficacy findings Comp
Corson SL
Hydro Thermablator (HTA)
versus rollerball (RB) ablation
N =276:
HTA=187
RB=89
Follow up=1 year
Goldrath NH
(3 year follow up on same patients)
HTA:
1 year:
Success: 77%
Amenorrhea: 40%
3 year:
Amenorrhea: 53%
Patient
satisfaction: 98%
RB:
1 year:
Success: 82%
2 cer
(one
2 pat
burns
Case
2 (HT
5 (RB
7 inc
secon
Amenorrhea: 51%
3 year:
Amenorrhea: 46%
Patient
satisfaction: 97%Goldrath reported the 3 year clinical follow up of
these same study participants [18]. At 36 months,
amenorrhea rates, reduction of bleeding to normal
levels or less, and patient satisfaction were tracked
with rates in the HTA group of 53%, 94%, and 98%
and in the RB group of 46%, 91%, and 97%,
respectively (Table 3).
A key advantage of this global endometrial
ablation device is that it is the only technique
guided hysteroscopically throughout the entire
procedure. Additionally, the HTA system is able to
treat the entire endometrial surface, including
those asymmetrically shaped or those distorted by
leiomyomas, as long as both tubal ostia are visible
on hysteroscopic examination. HTA can also be
applied to the office setting. Disadvantages are the
need for cervical dilatation, longer treatment
times, the risk of thermal burns to the vagina,
cervix and/or vulva, and the fact that hot water
stimulates pain [19]. Although pretreatment of the
endometrium is advocated in the pivotal FDA trial,
it is not considered mandatory.4. Her option cryoablation therapy
system
4.1. Device
The technique of cryotherapy has been shown to
achieve cell death through chemical damage or
intracellular ice formation. Historically, the use of
cryoablation to treat the endometrium was first
described in 1967 by Cahan and Brockunier [20].
They reported circulating liquid nitrogen at 80 to
100 8C through a 30 cm long cryosurgical probelications Reliability and validity issues
vical lacerations in RB group
complicated by septicemia)
ients with first-degree
in HTA group
s of hematometra:
A)
)
omplete HTA procedures
dary to technical difficulties
Study was not blinded
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was reduced in five out of the six study participants.
Droegemueller et al. reported using Freon instead of
liquid nitrogen in 16 patients with menorrhagia in
1971 [21]. 10 out of the 16 study participants were
successfully amenorrheic during the 6—8 week fol-
low up interval. Several decades later, CryoGen Inc.
developed the Her Option Cryoablation Therapy
System (American Medical Systems, Minnetonka,
Minnesota) which was approved by FDA for endome-
trial ablation in April 2001.
A 5 mm cryoprobe is inserted through the cervix
into the uterine cavity. The compressor system,
which is hermetically sealed, drives the unit as a
coolant is re-circulated and replenished through
the system. This function is based on the Joules—
Thompson principal that states that pressurized gas
produces a cooling effect when expanded through a
small orifice. An iceball with temperatures ranging
from 100 8C to 120 8C eventually forms around
the probe. Transabdominal ultrasonography follows
the growth of the ice ball, and the procedure is
stopped when it approaches the uterine serosa. The
ice front is identified on ultrasound by its echoge-
nicity and shadowing behind it. The endometrial
ablation process begins at the fundus and then the
cornua. Tissue necrosis lags approximately 3—4 mm
behind the ice front, because the temperature at
the edge of the iceball is approximately 0 8C, which
is nondestructive to tissue. Tissue necrosis occurs
at 15 8C to 20 8C [22]. The entire procedure
takes between 10—20 min.
4.2. Literature
The pivotal prospective, randomized controlled
trial of cryoablation versus rollerball ablation that
helped with FDA approval was published by Duleba
et al. [23]. 279 women with excessive uterine
bleeding characterized by PBAC’s greater than 150Table 4 Her option cryoablation therapy system
Author, patients Efficacy findings
Dubela et al. (pivotal
trial for FDA approval)
Cryoablation versus
rollerball (RB) ablation
N =279
Cryoablation:
1 year:
Amenorrhea: 27.6%
Success: 77.3%
2 year:
Cryoablation=193 No abnormal uterine bleeding: 9
RB=86 Satisfaction: 91%
Townsend et al. (2 year
follow up of same patients)
Rollerball:
1 year:
Amenorrhea: 55.6%
Success: 83.8%
2 year:
No abnormal uterine bleeding: 9
Satisfaction: 88%were enrolled in the study, with 193 women
randomized to the cryoablation arm, and 86 women
randomized to the rollerball ablation arm. All
patients received pretreatment with leuprolide
acetate 3.75 mg intramuscularly. The cryoablations
were performed with the Her option system under
transabdominal ultrasound guidance. The freeze
pattern consisted of a four-minute freeze with the
probe tip in one cornual area, and a six-minute
freeze in the contralateral cornual area. Patients
were excluded if they had a uterine cavity greater
than 10 cm or leiomyomas greater than 2 cm. A
success was defined as the patient reporting a
decrease in the PBAC score to less than 75. 77.3% of
the cryoablation patients, and 83.8% of the roller-
ball patients were a study success, with no
statistical significance between the two treatment
arms in terms of study success, improvement in
pain, mood and PMS symptoms. Interestingly there
was a significantly decreased amount of anesthesia
required for the endometrial cryoablation com-
pared to the rollerball ablation. The procedure was
well tolerated with patients reporting mild cramp-
ing and mild vaginal discharge. Townsend et al.
reported a 24 month follow up on these same study
participants [24]. 94% of women in the cryoablation
arm reported no abnormal uterine bleeding after
24 months, and 93% in the rollerball ablation group
reported no abnormal uterine bleeding after 24
months. 7% of the cryoablation and 8.1% of the
rollerball ablation patients proceeded to hysterec-
tomy at this time interval. A limitation of the
follow up study was the fact that the authors were
only able to receive information on 94 cryoablation
patients, and 43 rollerball arm patients (Table 4).
Advantages of the cryoablation system include
the minimal cervical dilation required for the
procedure, the lack of need for distension media,
and less pain due to the analgesic effects of
cryotherapy. As a result, this method of endome-Complications Reliability and validity issues
1 uterine perforation
with RB ablation
Study was not blinded
2 year information obtained
from only 94 cryoablation
patients, and 43 RB patients
4%
2%
H. Morgan, A.P. Advincula162trial ablation lends itself well to office-based
applications. Although pretreatment of the endo-
metrium was done in the pivotal FDA trial, it is not
necessary. The ability to visualize the advancing ice
front in real time under ultrasound guidance may
be considered an advantage however the need for
an ultrasound machine may also be looked upon as
a disadvantage. Other disadvantages of this system
are the lack of direct visualization of the uterine
cavity during the treatment process, longer treat-
ment times, and the absence of data regarding the
use of this technology in uteri with intracavitary
lesions.5. NovaSure
5.1. Device
The NovaSure device (Cytyc, Mountain View, CA) is
an impedance-controlled endometrial ablation sys-
tem, approved by the FDA in September 2001. This
technology uses bipolar radiofrequency (RF) energy
to desiccate and evacuate endometrial tissue. The
actual device uses suction to draw the endometri-
um toward a gold-plated bipolar mesh electrode
and to remove any generated vapor.
During an actual procedure, the cervix is dilated
to 8 mm and the protective sheath which contains
the bipolar electrode array is introduced. Once the
sheath is retracted, the preshaped bipolar elec-
trode array expands in the uterine cavity. Prior to
initiation of the ablation, an integrity check of the
endometrial cavity is performed. This is an auto-
matic safety feature that confirms uterine wall
integrity by injecting carbon dioxide into the
uterine cavity and testing that steady intrauterine
pressure is achieved and maintained prior to the
actual ablation process. Once successfully complet-
ed, bipolar RF energy is delivered to the endome-
trium up to 180 W until an impedance of 50 V is
reached. The power setting is based on the width
and length of the endometrial cavity which is
calculated beforehand. The system is designed to
provide less coagulation to the cornua and lower
uterine segment, and deeper necrosis to the rest of
the endometrium. The average treatment time is
90 s however the procedure also self-terminates
after 2 min.
5.2. Literature
Cooper et al. compared the NovaSure endometrial
ablation system to conventional rollerball (RB)
ablation in the pivotal trial for FDA approval [25].265 women with menorrhagia and PBAC scores of
150 or above for three consecutive months were
enrolled in the study. Patients were randomized
using a ratio of 2:1 to NovaSure versus RB
procedure. There was no pretreatment adminis-
tered. The authors reported a study success rate,
defined as a PBAC score of less than 75, in 88.3% of
the NovaSure patients, and 81.7% of the RB
patients. Reduction of bleeding to normal levels
or less (PBAC score of 100 or less) and amenorrhea
was reported in 90.9% and 41% of the NovaSure
patients respectively versus 87.8% and 35% in the
RB patients. The NovaSure procedure time was
significantly less at 4.2 min, compared to the RB
time of 24.2 min. Anesthesia requirements were
also less in the NovaSure group, with local and/or
IV sedation given alone in 73% of those patients
compared with 18% of the RB patients. Finally,
there were less intra-operative adverse events
with the NovaSure system than with the RB
approach with rates of 0.6% and 6.7% respectively.
The only NovaSure event was a bradycardia episode
after the device was inserted. In the RB group
there were three uterine perforations, and three
cervical lacerations. There were also significantly
less postoperative events with the NovaSure system
with rates of 13% versus 25.3% with the RB ablation
system (Table 5).
Bongers et al. performed a double-blind, ran-
domized, controlled trial comparing bipolar RF
endometrial ablation (NovaSure) to balloon endo-
metrial ablation (ThermaChoice) in a 2:1 ratio [26].
126 women with menorrhagia and PBAC scores of
150 or more were included in the study. All patients
had a normal uterine cavity measuring 6—11 cm.
Patients and their providers were unaware which
arm they had been randomized to, and the
ablations themselves were all performed by one
provider. 83 patients were randomized to the
NovaSure arm and 44 patients to the ThermaChoice
arm. The authors reported significantly higher
amenorrhea rates at 12 months in women who
had the NovaSure ablation (43%) than with the
ThermaChoice procedure (8%). The authors dis-
cussed this very low amenorrhea rate in the
ThermaChoice arm, and hypothesized that this
may have been lower than previously published
data secondary to the double-blinded nature of the
study. It should also be noted, however, that the
pretreatment protocols for the ThermaChoice sys-
tem were not followed. There was also a strong
decrease in the PBAC score after treatment with
the NovaSure than with the ThermaChoice arm.
The authors also found a 90% patient satisfaction
rate in the NovaSure arm, which was statistically
significant when compared to the 79% patient
Global endometrial ablation: A modern day solution to an age-old problem 163satisfaction in the ThermaChoice arm. Operation
time for the NovaSure was less than half the time
for the ThermaChoice procedure. A potential pitfall
to this study was the discovery of a technical failure
in the NovaSure generator after treatment of the
first 44 patients which required consideration
during and modification of the statistical analysis
(Table 5).
A significant advantage of the NovaSure system
is the extremely short treatment and procedure
time with no need for pretreatment of the endo-
metrium. This approach has also been associated
with minimal procedure related pain and as a
result, the potential for office use exist. A unique
feature of this device is the fact that the power
level of each procedure is calculated taking ac-
count the size of the uterine cavity thereby
allowing for customization with each patient.
Disadvantages of this system include the need to
dilate the cervix, the limitation of cavity size, and
the lack of hysteroscopic guidance during actual
treatment.6. Microsulis Endometrial Ablation (MEA)
6.1. Device
The use of microwave energy to treat menorrhagia
was first described in 1995 in the Lancet by Sharp et
al. [27]. The commercialized entity became known
as Microsulis Endometrial Ablation (Waterlooville,
Hampshire, UK) and eventually gained FDA approv-
al in September 2003. This approval included the
ability to apply this method of endometrial ablation
to patients with cavity measurements up to 14 cmTable 5 NovaSure
Author, patients Efficacy findings
Cooper et al. (pivotal trial
for FDA approval)
NovaSure versus rollerball
(RB) ablation
N =265
NovaSure=175
RB=90
Follow up=1 year
Bongers et al.
NovaSure versus
ThermaChoice ablation
N =126
NovaSure:
Success: 88.3%
PBACb100: 90.9%
Amenorrhea: 41%
Mean procedure time: 4.2 min
RB:
Success: 81.7%
PBACb100: 87.8%
Amenorrhea: 35%
Mean procedure time: 24.2 min
NovaSure:
Amenorrhea: 43%
NovaSure=83 Patient satisfaction: 90%
ThermaChoice=43 ThermaChoice:
Follow up=1 year Amenorrhea: 8%
Patient satisfaction: 79%and fibroid-associated cavity distortions of less
than 3 cm.
This novel technique consists of a control unit
with foot pedal and a reusable hand-held device
with an 8.5 mm diameter probe that is attached to
an ergonomic handle. Microwave energy is gener-
ated by a magnetron and passed along the tip of the
probe at a frequency of 9.2 GHz, at 30 W. The
absorption of microwave energy leads to generated
heat which is conducted deeper into the tissue in
order to destroy the basalis layer. Because thermal
penetration occurs up to approximately 5—6 mm,
myometrial measurements should be determined in
order to identify a possible risk of penetration to
the serosal surface of the uterus during application.
During an actual treatment, the cervix is dilated to
8—9 mm, and the microwave probe is inserted to
the level of the mid-fundus. The probe is activated
by a foot switch and the temperature quickly rises
to the therapeutic range from 70 8C to 80 8C as the
microwave energy is absorbed. The probe is then
moved laterally to the bilateral cornua in a
bsweeping motionQ and then throughout the cavity
so as to assure coverage. Intrauterine temperatures
are monitored by thermocouplers on the external
surface of the probe thereby providing real time
monitoring of the treatment progress. The treat-
ment time is approximately 3—4 min.
6.2. Literature
A review of several randomized controlled trials has
shown excellent outcomes. Cooper et al. per-
formed the pivotal randomized controlled multi-
center trial comparing MEA to traditional rollerball
ablation that helped gain FDA approval [28]. This
study was unique in that women with uterineComplications Reliability and
validity issues
NovaSure:
Patient with bradycardic episode
RB:
3 uterine
perforations
3 cervical lacerations
4 NovaSure procedures not performed:
(2) uterine cavityN10
(2) t-shaped uteri
Detection of technical failure of NovaSure
generator after treatment of 44 patients
Study was not
blinded
None
Table 6 Microsulis Endometrial Ablation (MEA)
Author, patients Efficacy findings Complications Reliability and
validity issues
Cooper et al. (pivotal trial
for FDA approval)
Microwave endometrial
ablation (MEA) versus
rollerball (RB) ablation
N =322
MEA=215
RB=107
Inclusion criteria: PBAC score
greater than 185
Uterine cavities up to 14 cm
Fibroid less than 3 cm allowed (22%)
Follow up=1 year
MEA:
Reduction in PBAC to l
ess than 75: 96.4%
Amenorrhea: 61.3%
Treatment time: 3.45 min
RB:
Reduction in PBAC to
less than 75: 92.7%
Amenorrhea: 51%
Treatment time: 20.26 min
Two cervical lacerations
in both the MEA and RB arms
Study was not blinded
H. Morgan, A.P. Advincula164cavities up to 14 cm were included, and approxi-
mately 22% of the patients in the study had fibroids
less than 3 cm. All patients received pretreatment
with leuprolide acetate depot 3—5 weeks prior to
operative treatment. The primary outcome mea-
sure of this study was a reduction of the PBAC score
to 75 or less, which defined a study success. In
terms of evaluable patients, 96.4% of the micro-
wave patients, and 92.7% of the rollerball patients
were study successes. This study reported large
amenorrhea rates for both the microwave and the
rollerball arms of 61.3% and 51% respectively. The
amenorrhea rate for the patients with fibroids in
the MEA arm was 61.3% compared with 38.5% in the
rollerball arm. Of note, this study did find that the
microwave technique was more successful than
rollerball ablation in treating patients with a body
mass index (BMI) of 30 or greater (Table 6).
In another study, Cooper et al. compared
microwave ablation to rollerball ablation in 263Table 7 Microsulis Endometrial Ablation (MEA)
Author, patients Efficacy findings
Cooper et al.
Microwave endometrial
ablation (MEA) versus
rollerball (RB) ablation
N =263
MEA=129
RB=134
Follow up=1 year
Bain et al. (2 year follow
up on same patients)
MEA:
Mean operating time: 11.4 min
1 year:
Completely or generally satisfied: 77%
Amenorrhea: 40%
2 year:
Completely or generally satisfied: 79%
Amenorrhea: 47%
RB:
Mean operating time:
15 min
1 year:
Completely or generally satisfied 75%
Amenorrhea: 40%
2 year:
Completely or generally satisfied: 67%
Amenorrhea: 41%women, randomized at a 1:1 ratio [29]. The
primary outcome measure was patient satisfac-
tion. They only included patients who had uteri
that palpated to less than 10 weeks size on
bimanual examination. All patients received pre-
operative endometrial preparation with goserelin
3.6 mg. All but 11 of the procedures were
performed by two surgeons, each of whom had
previously performed at least 50 rollerball abla-
tions. 77% of the microwave and 75% or the
rollerball patients were totally or generally satis-
fied with their treatments. Both techniques led to
significant and equivalent reductions in pain and
bleeding with amenorrhea rates of 40% for both
groups. Of note, there were a number of postop-
erative complications in the rollerball group
(Table 7).
Bain et al. reported 2 year follow up data on
these same patients [30]. They reported that
patients expressed greater satisfaction with theComplications Reliability and
validity issues
MEA system failures in 4 patients
One blunt perforation in each
group with one immediate
hysterectomy required in the RB group
Readmit of 1 RB patient with
pain leading to hysterectomy
Bleeding in 5 RB patients requiring
Foley bulb tamponade
Excess fluid deficit in 1 RB patient
requiring procedure to be aborted
Study was
not blinded
Global endometrial ablation: A modern day solution to an age-old problem 165microwave procedure, with 79% of microwave
patients stating that they were either completely
or generally satisfied with their results, compared
to 67% of the rollerball patients. This was statisti-
cally significant. There was however no statistical-
ly significant difference in the rates of amenorrhea
achieved between the two groups, with a rate of
47% in the microwave group, and 41% in the
rollerball group. The need for further surgical
intervention was similar for both arms of the study
in that 11.6% of the microwave patients and 12.7%
of the rollerball patients had hysterectomies
performed during the 2 year follow up interval
(Table 7).
Advantages of the MEA system include the short
treatment time, and the ability to apply this
method of endometrial ablation to patients with
cavity measurements up to 14 cm and fibroid-
associated cavity distortions of less than 3 cm.
Additional advantages of the system are the lack of
requirement for uterine pretreatment as shown by
Fortin et al. applicability to an office-based
surgical practice, and the ability to perform
hysteroscopic sterilization for permanent contra-
ception following MEA procedures [31—33]. The
need to dilate the cervix and the need to assess
myometrial thickness with an ultrasound prior to
treatment are disadvantages of this approach.7. Conclusion
The evolution of endometrial ablation to its current
state with second generation devices has allowed
gynecologists to continue to manage menorrhagia
in a minimally invasive fashion. An efficacy that
parallels traditional hysteroscopic ablative techni-
ques has been of paramount importance as seen in
this review of the literature while also improving
the safety profiles and ease of use of these devices.
As a result of these changes, there has also been a
trend towards the performance of these procedures
in an office setting.
Critical to the successful use of these technolo-
gies is careful patient selection. A proper preoper-
ative work up is necessary before initiation of any
therapy for menorrhagia. Additionally, it is ex-
tremely important to understand the technical
differences between devices since each one is
designed for use in women with specific uterine
anatomies. This is further evidenced by the wide
variation in destructive modalities, treatment
times, need for endometrial pretreatment, and
complications encountered. In the end, a global
understanding of these devices will allow gyneco-
logic surgeons to enhance patient care with ad-vanced technologies that provide an alternative to
hysterectomy.References
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